PALISADE BIO, INC. financials

PALI CIK 0001357459

Source: EDGAR filings · Built 2026-06-02T03:46:47Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -12.19M -11.14M -13.37M -14.77M -4.77M
EBITDA -18.05M -14.86M -13.07M -15.72M -41.85M -9.29M
Working Capital 129.59M 7.26M 10.74M 11.72M 9.01M -7.19M
Net Debt -133.38M -9.73M -12.22M -12.07M -10.30M 708.00K
Operating Margin -5228.00% -68764.79%
Net Margin -4920.00% -76346.15%
Return on Equity (ROE) -12.97% -192.71% -108.72% -114.27% -361.38% 62.17%
Return on Assets (ROA) -12.49% -132.70% -87.53% -90.47% -212.72% -341.90%
Current Ratio 28.95× 3.24× 5.15× 4.89× 4.61× 0.11×
Debt-to-Equity 0.00× 0.01× 0.02× 0.03× 0.03× -0.09×
Cash Conversion Ratio 0.65× 0.84× 0.91× 0.94× 0.56× 0.46×
Accruals Ratio -0.04× -0.21× -0.08× -0.06× -0.95× -1.84×
SBC % of Revenue 249.60% 14896.45%
CapEx Coverage -2783.25× -1336.00× -794.67×
Free Cash Flow Per Share $-8.61 $-24.42 $-15.19 $-79.02 $-1.72

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 1.46× 180.59×
P/B 2.90× 0.61× 0.03× 1.23× 0.05×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 0 250.00K 0
Research and Development Expense 16.00M 362.00K 2.02M
Operating Expenses 18.06M 14.86M 13.32M 15.72M 41.85M 9.30M
Operating Income (Loss) -18.06M -14.86M -13.07M -15.72M -41.85M -9.30M
Income Tax Expense (Benefit) 0 0 0 0 0 1.00K
Net Income (Loss) Attributable to Parent -16.78M -14.44M -12.30M -14.26M -26.62M -10.32M
Earnings Per Share, Basic $-0.30 $-10.19 $-27.01 $-16.53 $-142.95 $-3.72
Weighted Average Number of Shares Outstanding, Basic 55.67M 1.42M 456,014 880,311 186,195 2.77M
Earnings Per Share, Diluted $-0.30 $-10.19 $-27.01 $-16.53 $-169.74 $-3.72
Weighted Average Number of Shares Outstanding, Diluted 55.67M 1.42M 456,014 880,311 186,958 2.77M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 133.38M 9.82M 12.43M 12.38M 10.49M 713.00K
Assets, Current 134.22M 10.49M 13.33M 14.73M 11.51M 896.00K
Assets 134.34M 10.88M 14.05M 15.76M 12.51M 3.02M
Long-term Debt 87.00K 1.14M
Liabilities, Current 4.64M 3.24M 2.59M 3.01M 2.50M 8.08M
Long-term Debt, Excluding Current Maturities 0 94.00K
Liabilities 4.96M 3.39M 2.74M 3.28M 5.15M 10.12M
Stockholders' Equity Attributable to Parent 129.38M 7.49M 11.31M 12.48M 7.37M -16.60M
Common Stock, Shares, Outstanding 159.44M 2.77M 618,056 2.94M 284,780 2.77M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -10.85M -12.19M -11.13M -13.36M -14.77M -4.77M
Payments to Acquire Property, Plant, and Equipment 0 4.00K 10.00K 0 6.00K
Net Cash Provided by (Used in) Investing Activities 0 -4.00K -10.00K -54.00K -6.00K
Net Cash Provided by (Used in) Financing Activities 134.44M 9.58M 11.19M 15.26M 24.61M 1.89M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PALI CIK 0001357459), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

EVH

Evolent Health, Inc.

OFG

OFG Bancorp

XOMA

XOMA Royalty Corporation